Raman Molecular Imaging to Determine Postoperative Oncological Outcomes in Patients with Prostate Cancer
In conjunction with the Allegheny Health Network Department of Urology, ChemImage researchers have submitted an abstract to the American Association for Cancer Research (AACR) outlining our innovative use of Raman Molecular Imaging (RMI) in patients with prostate cancer. The aim of this study was to evaluate RMI as a methodology for predicting the outcome of prostate cancer patients following radical prostatectomy.
38 patients who underwent prostatectomy between 2009 and 2011 were prospectively enrolled with mean (median) age of 60 (61) years old. The results successfully indicate that RMI of prostatectomy tissue can distinguish progressor patients from NED patients.
This preliminary work lays the foundation for the further study of RMI for evaluating prostate tissue and developing an assay which would positively impact clinicians and patients with prostate cancer.
About ChemImage Corporation
ChemImage Corporation is a Pittsburgh based company committed to making the world healthier and safer through dramatic advancements in chemical imaging technology. The company combines proprietary, state-of-the-art imaging sensors, algorithms and analytical software to solve the world's most challenging health and safety issues.
ChemImage seeks to provide an Awareness of Things™ (AoT™) to a global audience, using the company's innovation platforms to provide people with unprecedented levels of vision, information and situational knowledge about their surroundings in their everyday lives. To accomplish this goal, the firm develops technologies for chemical and biological applications across many global industries; including life sciences, bio-medical, security, threat detection, anatomic pathology, forensics and diagnostics.
For more information, contact ChemImage.